KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Non-Current Debt (2018 - 2025)

Historic Non-Current Debt for Castle Biosciences (CSTL) over the last 5 years, with Q3 2025 value amounting to $10.0 million.

  • Castle Biosciences' Non-Current Debt rose 33.95% to $10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 33.95%. This contributed to the annual value of $9.7 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Castle Biosciences' Non-Current Debt is $10.0 million, which was up 33.95% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Non-Current Debt ranged from a high of $10.0 million in Q3 2025 and a low of $8.1 million during Q2 2025